Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Net Income towards Common Stockholders: 2010-2018

Historic Net Income towards Common Stockholders for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Sep 2018 value amounting to -$14.4 million.

  • EyePoint Pharmaceuticals' Net Income towards Common Stockholders fell 139.24% to -$14.4 million in Q3 2018 from the same period last year, while for Sep 2018 it was -$34.6 million, marking a year-over-year decrease of 99.88%. This contributed to the annual value of -$53.2 million for FY2018, which is 187.64% down from last year.
  • As of Q3 2018, EyePoint Pharmaceuticals' Net Income towards Common Stockholders stood at -$14.4 million, which was down 46.89% from -$9.8 million recorded in Q2 2018.
  • Over the past 5 years, EyePoint Pharmaceuticals' Net Income towards Common Stockholders peaked at $20.6 million during Q3 2014, and registered a low of -$14.4 million during Q3 2018.
  • Over the past 3 years, EyePoint Pharmaceuticals' median Net Income towards Common Stockholders value was -$6.0 million (recorded in 2017), while the average stood at -$6.4 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first spiked by 657.80% in 2014, then tumbled by 8,568.66% in 2017.
  • EyePoint Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$4.1 million in 2014, then fell by 27.26% to -$5.2 million in 2015, then surged by 98.71% to -$67,000 in 2016, then slumped by 8,568.66% to -$5.8 million in 2017, then slumped by 139.24% to -$14.4 million in 2018.
  • Its Net Income towards Common Stockholders stands at -$14.4 million for Q3 2018, versus -$9.8 million for Q2 2018 and -$4.7 million for Q1 2018.